Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Half of Member Companies Report Price Settlements: Qol-Led Open Tender
August 8, 2014
- Linical Aims to Become “One-Stop” CRO for Global Clinical Trials
August 8, 2014
- Daiichi Sankyo Collaborates with US Venture for Analgesic in the US
August 8, 2014
- Daiwa Corporate Investment Establishes Venture Capital Firm Specializing in Biopharmaceuticals; Sights Set on Seeds of University Origin
August 7, 2014
- Development of Material for Treating Cartilage Injury Selected by NexTEP: Mochida
August 7, 2014
- Kyowa Kirin’s UK Subsidiary Completes Acquisition of Archimedes Pharma
August 7, 2014
- Santen Includes FY2017 Sales Target of 205 Billion Yen and Globalization in New Business Plan
August 6, 2014
- ASKA to Launch Blopress AGs on Sept 12
August 6, 2014
- Hisamitsu to Dissolve US JV with Novartis Pharmaceuticals
August 6, 2014
- Eli Lilly Japan Files NDA for GLP-1 Receptor Agonist Dulaglutide
August 6, 2014
- Eisai Ends Development of Diabetic Complication Treatment
August 5, 2014
- Development of Antibody Drugs Accelerating in the Field of Asthma; First New Option Could Be Available as Early as 2016
August 5, 2014
- Otsuka, UCB Japan File E Keppra Injectable for Monotherapy
August 5, 2014
- Celgene Files NDA for Hematopoietic Malignancy Treatment Pomalidomide in Japan
August 5, 2014
- Kyowa Kirin Files NDA for Antithrombin Preparation KW-3357
August 5, 2014
- Asahi Kasei Pharma Files NDA for Xiaflex for Treatment of Dupuytren’s Contracture
August 4, 2014
- Taiho to Terminate Multinational PIII Study of Angiogenesis Inhibitor Orantinib for Hepatocellular Carcinoma
August 4, 2014
- Daiichi Sankyo to Transfer Akita Plant to Alfresa Pharma
August 4, 2014
- Kyowa Kirin, AstraZeneca Hook Up in Immuno-Oncology Clinical Study
August 1, 2014
- Kyowa Kirin Taking Nesp Issue Seriously from Ethical Standpoint: Pres.
August 1, 2014
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…